BEDFORD, Ohio, April 18, 2011 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline. Topotecan Hydrochloride for Injection is indicated for the treatment of metastic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Additionally, this product is used to treat small cell lung cancer. It is used in combination with cisplatin to treat cancer of the cervix, which cannot be treated with surgery or radiation therapy.
Bedford Laboratories Topotecan Hydrochloride for Injection, 4 mg (base)/vial is sold individually and is latex free, UPC bar coded and preservative free. This launch is an example of how Bedford Laboratories goes Beyond, Above-and-Beyond™ to provide our customers with pharmaceutical products that improve people's health and quality of life.
Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories produces an extensive selection of critical-care and medically necessary medications, including oncology products, cardiac agents, anesthesia products and other therapeutic class injectables. We recognize the importance of making sure that physicians and patients have access to the products they need when they need them. At Bedford Laboratories, quality is paramount. We take the utmost care in producing a high-quality reliable product supply to the market.
About Ben Venue Labora